Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy

- C3 glomerulopathy (C3G) defines a group of untreatable ultra-rare renal diseases.
- C3G is caused by dysregulation of the alternative complement pathway.
- Nearly half of C3G patients progress to end stage renal failure within 10 years.
- Cp40, a compstatin analog, inhibits complement by binding to C3 and C3b.
- Cp40 may offer a novel and promising therapeutic option to C3G patients.